Research Interests for Henry G. Grabowski

Professor Grabowski specializes in the investigation of economics in the pharmaceutical industry, government regulation of business, and the economics of innovation. His specific interests within these fields include intellectual property and generic competition issues, the effects of government policy actions, and the costs and returns to pharmaceutical R&D. He has been publishing research papers for over four decades, from his earlier work, “The Effects of Regulatory Policy on the Incentives to Innovate: An International Comparative Analysis” with John Vernon and Lacy Glenn Thomas, to his more recent projects including, “Impact of Economic, Regulatory and Patent Policies on Innovation in Cancer Chemoprevention” with Jeffrey L. Moe. His latest research studies include other such titles as, “Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R&D Productivity” with Margaret Kyle; “Should the Patent System for New Medicines Be Abolished?” with J.A. DiMasi; and several others. Professor Grabowski has served as an advisor and consultant to various organizations, offering his ideas and insights gained through his extensive investigations to the National Trade Academy of Sciences, the Institute of Medicine, the Office of Technology Assessment, the Federal Trade Commission, and the General Accounting Office. His latest project involved an analysis for the FTC concerning public policy, competition and investment in the “Next Generation of Biologics.”

Keywords:

Anti-Infective Agents, Antineoplastic Agents, Antiparasitic Agents, Biomedical Research, Biotechnology, Chemoprevention, Clinical Trials as Topic, Cohort Studies, Commerce, Costs and Cost Analysis, Data Collection, Developing Countries, Drug and Narcotic Control, Drug Approval, Drug Costs, Drug Discovery, Drug Industry, Drug Utilization, Drugs, Generic, Drugs, Investigational, Economic Competition, Europe, Formularies as Topic, Health Policy, Health Services Accessibility, Humans, Income, Intellectual Property, Investigational New Drug Application, Law, Legislation, Drug, Liability, Legal, Marketing, Medicaid, Neoplasms, Orphan Drug Production, Patents as Topic, Pediatrics, Pharmaceutical industry, Policy Making, Political science, Poverty, Product Surveillance, Postmarketing, Program Development, Raloxifene, Regression Analysis, Reimbursement, Incentive, Research Support as Topic, Safety, United States, United States Food and Drug Administration, United States Office of Technology Assessment, World Health

Current projects:

Testimony and Public Policy Comments

Recent Publications

1. H.G. Grabowski, C. Brain , A. Taub and R. Guha, Pharmaceutical Patent Challenges: Company Strategies and Litigation Outcomes, American Journal of Health Economics, vol. 3 no. 1 (Winter, 2017), pp. 33-59 [AJHE_a_00066], [doi]
2. with Richard Manning, Key economic and value considerations in the U.S. market for plasma protein therapies (February, 2018), Bates White Economic Consulting [view]
3. Grabowski, HG; Marriott, Z; Kovacheva, P; Elzinga, A, One Year after the Launch of the First U.S. Biosimilar Drug: Lessons for the Future? (August, 2017)
4. Grabowski, H; Brain, C; Taub, A; Guha, R, Pharmaceutical Patent Challenges: Company Strategies and Litigation Outcomes, American Journal of Health Economics, vol. 3 no. 1 (February, 2017), pp. 33-59, University of Chicago Press [doi]
5. Grabowski, H; Long, G; Mortimer, R; Boyo, A, Updated trends in US brand-name and generic drug competition, Journal of Medical Economics, vol. 19 no. 9 (September, 2016), pp. 836-844, Informa UK Limited [doi]